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Abstract
Cells are regulated by networks of controllers having many targets, and targets affected by many controllers, in a ‘‘many-to-
many’’ control structure. Here we study several of these bipartite (two-layer) networks. We analyze both naturally occurring
biological networks (composed of transcription factors controlling genes, microRNAs controlling mRNA transcripts, and
protein kinases controlling protein substrates) and a drug-target network composed of kinase inhibitors and of their kinase
targets. Certain statistical properties of these biological bipartite structures seem universal across systems and species,
suggesting the existence of common control strategies in biology. The number of controllers is ,8% of targets and the
density of links is 2.5%61.2%. Links per node are predominantly exponentially distributed. We explain the conservation of
the mean number of incoming links per target using a mathematical model of control networks, which also indicates that
the ‘‘many-to-many’’ structure of biological control has properties of efficient robustness. The drug-target network has many
statistical properties similar to the biological networks and we show that drug-target networks with biomimetic features can
be obtained. These findings suggest a completely new approach to pharmacological control of biological systems.
Molecular tools, such as kinase inhibitors, are now available to test if therapeutic combinations may benefit from being
designed with biomimetic properties, such as ‘‘many-to-many’’ targeting, very wide coverage of the target set, and
redundancy of incoming links per target.
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Introduction
Control of cellular function depends on bipartite (two-layer)
networks, in which one class of nodes (the controller) acts on the
other class (the target) to regulate its function. Examples of cellular
control networks include transcription factors, microRNAs, and
protein kinases, which control genes, mRNA transcripts, and
protein substrates, respectively. In these networks, the control layer
interacts with the target layer in a combinatorial, ‘‘many-to-many’’
fashion (see Figure 1). In other words, each controller has many
targets, the targets themselves are under the influence of many
controlling molecules, and the target sets of different controllers
overlap. Moreover, the number of controllers is usually signifi-
cantly lower than the number of targets. This ‘‘many-to-many’’
structure is well recognized in biological systems [1], not only in
intracellular control but also in many other types of complex
control in biology, including the nervous system (see Text S1,
section S1.1).
The idea of a many-to-many bipartite control structure is
similar to the concept of dense overlapping regulon (DOR) [2] in
bacterial gene networks, which indicates a motif (i.e. a pattern that
recurs within a network), in which transcription factors and genes
are connected through many overlapping interactions. Here we
extend this concept to different biological structures and describe
the many-to-many property as a feature of entire control networks,
for different types of control molecules, contrasting it with the
other possible bipartite structures, such as one-to-one and one-to-
many, described in Figure 1. One important question concerns the
statistical properties of these control structures with strong overlap
and redundancy. It was shown [2] that dense overlapping regulons
deviate substantially from random networks. Here we explicitly
characterize the global statistical properties of several bipartite
control structures, and we show that the degree distribution of the
two types of nodes is well approximated by exponentials.
A key issue related to network topology is robustness. What are
the advantages of the ‘‘many-to-many’’ structure in terms of
robustness, and why, as we show here, do some parameters of the
networks seem to be universal across different control structures
and species? In order to explore the link between the network
properties and robustness we introduce a simplified Boolean
signaling model. Boolean network models of biological regulation
were first pioneered by Kaufmann [3] [4], and have been used to
model specific interactions in small, well-characterized biological
pathways [5,6,7]. The control problem – i.e. calculating the
specific input sequence required to achieve a desired output – has
also been explored within these systems [8,9]. None of these
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two classes of nodes in which there are no links between nodes of
the same class. While there have been many genome-wide network
analyses [10,11,12,13,14,15], and one recent work on co-
regulation of transcription and phosphorylation networks [16],
here we focus exclusively on universal features of bipartite
networks, neglecting the fact that some of the targets might also
act in turn as controllers on other downstream biological entities
or on other targets. This simplified approach captures some
peculiar and universal properties of control in biology that may
help design biomimetic drug-target control strategies.
Results
Naturally occurring biological control networks share
statistical properties
We examine quantitative characteristics of three biological
control systems in three different species (human, yeast, and E.
coli), from the perspective of bipartite combinatorial control. First
we consider the numbers of nodes. Table 1 (upper left) shows
estimates of the number of controllers and targets from the
literature for the three types of networks in humans. Notably,
though these numbers are from three different cellular systems of
varying size, the ratios of control nodes to target nodes are similar,
approximately 8% (Table 1, upper left). We also measured the
controller/target ratio in several molecular interaction databases.
These databases are sparse and therefore provide less confident
estimates than the literature, but we found a similar mean value:
8.9% (albeit with much higher variability).
Next, we use molecular interaction databases to explore
connectivity parameters of bipartite networks in nature. Networks
were extracted from publicly available databases and separated
into controller nodes (microRNA, transcription factors, protein
kinases) and target nodes (mRNA transcript, gene, protein
substrates), with directed links between controllers and targets.
We quantified properties including density of links (existing links
divided by the number of possible links), distribution of links for
each type of node, and overlap between the target sets of different
controllers. In these datasets, the percentage of targets that also act
as controllers is very small and sizeable only in the human
transcription factor network (1.6%) and in the human kinase
network (16%) (see Text S1, section S1.2 and Table S1 for more
details).
Table 1 shows that these networks share specific network-wide
properties despite wide variation in the number of nodes,
complexity of species, and type of molecular interaction. As
mentioned above, the mean controllers per target (M/N) over all
biological networks was 8.9%. Detailed analysis of Gene Ontology
(GO) enrichment of targets is described in Text S1 section S1.2,
Figure S1, and Tables S2 and S3. Analyses of the two measures of
overlap (Shared Targets per Controller and Pairwise Overlap of
Targets, see Figure S2 for an illustrative definition) are described
in Text S1 section S1.3 and Table S4.
We have observed that the networks in the databases are all
characterized by the presence of a giant connected component. In
particular, the human and yeast transcription factor, human
miRNA, and kinase inhibitors networks are completely connected.
Human and yeast kinase networks contain a few disconnected
components with two and three nodes. Only in the E. coli
transcription factor network there is a considerable fraction of
nodes (7%) outside the giant component. These nodes are grouped
in many disconnected small components of size ranging from 2 to
11.
We explored properties of the node degree distributions in the
bipartite networks. Figure 2 shows distributions of links per node k,
for incoming links per target (controllers per target, kin) and
outgoing links from controllers (targets per controller, kout).
Figure 2A depicts the empirical cumulative distribution function
(cdf) for all datasets, normalized by the average links per node
,k. and overlaid on a standard exponential cdf (solid line).
Figures 2B and 2C compare histograms of each network with
bipartite random networks of the same size (a modified Erdo ¨s-
Re ´nyi random graph model in which edges between controllers
and targets are generated with constant probability, see Methods).
Only the human transcription factor network has a peak in its
outgoing link distribution that is compatible with the binomial
Figure 1. Possible combinatorial control strategies. There are several qualitatively different structures for control networks of M controllers
(x1,x2,…xM) and N targets (y1,y2,…yN). In the one-to-one case (left panel), M=N.
doi:10.1371/journal.pone.0029374.g001
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incoming links in the kinase inhibitor network also show a possible
binomial component. Otherwise, most curves approximate an
exponential distribution, which is not consistent with a bipartite
random graph model (further analyses of curve-fitting and link
distributions are provided in Text S1 sections S1.4, S1.6, Figures
S3, S4, S5, S6, and S7, and Table S5).
Notably, the average ,kin. of targets lies within the narrow
range between 2 and 10 for all networks studied, a phenomenon
which we explore below in more detail using a mathematical
model. These global averages cannot be statistically tested against
a degree-preserving null model, however, as the randomized
networks would have exactly the same average values of incoming
and outgoing links as the test network. We instead used degree-
preserving randomization to test correlations between kout and kin
for each network (see Text S1 section S1.5 and Figure S8),
following the method described by Maslov et al. [17]. Though
these in-degree/out-degree correlation patterns were not found to
be as robustly conserved as other statistical properties, the analysis
reveals trends that may be interesting avenues for future research.
All biological networks had similar sparse link density, realizing
an average of only 2.5%61.2% of all possible controller-to-target
interactions. Link density D is related to the average links per node
by the equation [18]
D~
SkinT
M
~
SkoutT
N
, ð1Þ
where ,kin. is the average incoming links over N target nodes,
and ,kout. is the average outgoing links from M controller nodes.
Note that
SkinT
SkoutT
~
M
N
, ð2Þ
suggesting that similarities in the ratios of nodes may be related to
constraints on the average incoming and outgoing links per node.
A drug-target network with biomimetic properties can
be sampled from a large drug library
We also analyzed a drug target network composed of 38 kinase
inhibitors and of their kinase targets [19]. This network has also a
many-to-many structure and its properties have similarities but are
not identical to the biological ones (see Table 1 and Figure 2).
This published drug-target dataset was a small sample, however,
compared to existing libraries of thousands of fully profiled (i.e.,
with known targets) kinase inhibitors owned by pharmaceutical or
biotech companies. Information about the size of these profiled
libraries can be found in some official documents (e.g, see Ambit
IPO S-1 SEC 2010 filing). In the absence of drug-target data from
these proprietary libraries, we therefore simulated a kinase
inhibitor library of a comparable size. We simulated the drug-
target network for a hypothetical library of 1500 compounds,
creating target profiles that gave the same target per controller and
controller per target distributions as the 38-drug network in
Table 1. Network parameters for various types of combinatorial control within cells.
Literature Network databases
Human Human Yeast E. coli Drug
Node properties TF Kinase miRNA TF Kinase miRNA TF Kinase TF KI
Controllers (M) 1,800* 518 940 389 264 153 186 88 169 38
Targets (N) 20,500N 6,150{ 11,890{ 9284 988 9448 6297 1341 1495 316
M/N (%) 8.8% 8.4% 7.9% 4.2% 26.7% 1.6% 3.0% 6.6% 11.3% 12.0%
Link properties
Outgoing links from controllers (mean kout) 181 8.9 359 229 46 20 78.8
Incoming links per target (mean kin) 7.6 2.4 5.8 6.8 3 2.3 9.48
Link density 1.9% 0.9% 3.5% 3.6% 3.5% 1.3% 25.0%
Shared targets per controller (mean) 98% 73% 95% 98% 85% 74% 100%
Pairwise overlap of targets (mean) 4.5% 7.1% 7.1% 6.3% 8.3% 1.1% 33.8%
Statistical values of selected parameters
Parameter Mean SD CV 95% lo 95% hi
M/N (literature) 8.4% 0.5% 0.054 7.5% 9.3%
Incoming links per target (kin) 4.7 2.4 0.51 0.016 9.3
Link density 2.5% 1.2% 0.50 0.041% 4.9%
Shared targets per controller 87.2% 11.6% 0.13
Pairwise overlap of targets 5.7% 2.6% 0.45 0.6% 10.8%
*Vaqueriza et al. [51] estimate 1,700–1,800 human transcription factors.
NOther estimates for the number of human genes are in the range 20,000–25,000.
{Friedman et al. [40] estimate 58% of genes are targeted by miRNA (11,890=.58*20,500).
{Cohen et al. [52] estimate 30% of human proteins are phosphoryated (6,150=.30*20,500).
The ratio of controllers per target drawn from the literature is similar across different types of biological network in humans, approximately 8%. Node properties differ
between the literature and network databases owing to incomplete information in the databases. Link density is the ratio of the number of actual links to the number of
possible links. Shared targets per controller and pairwise overlap are measurements of overlapping target sets described in the Text S1, section S1.3. SD=standard
deviation, CV=coefficient of variation.
doi:10.1371/journal.pone.0029374.t001
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PLoS ONE | www.plosone.org 3 January 2012 | Volume 7 | Issue 1 | e29374Figure 2. Distributions of incoming and outgoing links for several types of combinatorial control networks. (A) Cumulative
distributions of links per node in each of the networks of Table 1 were normalized by the mean and plotted together on log-log axes, alongside the
discrete analog to the exponential distribution (solid line), see Methods. By contrast, a power-law, or scale-free, distribution would produce a straight
line in this log-log plot. (B) Individual histograms of targets per controller (outgoing links from controllers, kout), and (C) controllers per target
(incoming links per target, kin) plotted for each individual network. The three human networks were combined based on shared targets (top right of
each panel). Horizontal axes in (B) and (C) are normalized to the total number of target or controller nodes, respectively in each network. Each
distribution is compared with the binomial distribution expected from a bipartite random graph with identical numbers of nodes and links (dashed
curve). An exponential curve is also fitted to each dataset (solid line). Note that the kinase inhibitor network shown here is distributed over a much
wider range on the x-axis than the biological networks.
doi:10.1371/journal.pone.0029374.g002
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by sampling existing drug libraries, it is possible to identify sets of
kinase inhibitors with statistical properties very similar to those of
biological controllers.
The simulated library was created using the inverse sampling
transform method, which requires the analytic inversion of the
cumulative distributions of the theoretical distributions we want to
sample [20]. This method is used both for targets and for controllers.
A link-matching procedure is then implemented to randomly match
‘‘links out’’ of kinase inhibitors with ‘‘links in’’ into kinase nodes,
creating a bipartite network with the desired link distributions. We
show in Figure S9 the outgoing links from controllers and incoming
links per target for a simulated network obtained with this procedure.
Once a sample kinase inhibitor/kinase network has been
created, we have used a rejection method approach [20] to
identify a subset of inhibitors having an exponential distribution,
but a reduced average value for ,kout., more similar to our
measurements in the naturally occurring networks. The rejection
method consists in picking randomly an inhibitor node with a
kout=k, and keeping it in the set with probability p(k)~
1
kout,BM
1{
1
kout,BM
   (k{1)
, where kout,BM is the ideal biomimetic
value. In implementations using a real drug library, biological
information about the targets can be incorporated, using a
modified alternative of the sampling algorithm (see Methods for
details).
The simulated library (see also Figure S9) is composed of 1,500
kinase inhibitors targeting all the 518 kinases in the human
genome. In this larger library the average kout was 55 and the
average kin was 159. The smaller sampled library composed of 60
kinase inhibitors targeting 486 kinases (a coverage of 93.8% of all
kinases). In this library the average kout was 43 and the average kin
was 5.3. The statistical parameters of the sampled library are
closer to the naturally occurring ones shown in Table 1.
A Boolean bipartite model shows dependence of
robustness on ,kin.
The many-to-many network structure, with parameters spanning
comparatively limited ranges, may be the result of an optimized
trade-off between efficient use of biological resourcesand robustness
(via redundancy) to variation in environmental and genetic inputs.
To maximize redundancy, a high average incoming link per target
value is clearly preferable. We built a model to simulate redundancy
and robustness in a bipartite signaling network. A set of
transcription factors, for example, takes on its expression state
according to upstream signaling events, and induces an output gene
expression state throughits network of targets. Nowconsider a setof
M controller nodes, which can take on 2
M binary states. Controllers
are randomly connected to N target nodes having average incoming
links ,kin., and each target node takes on a binary state according
to a Boolean rule on unweighted links (see Methods). We can then
derive the number of unique output sequences V that the network
can achieve, and the robustness R of an output state to mutations
(link deletions), given values of M, N, and ,kin..
In Figure 3, analytical solutions for V and R are plotted as a
function of ,kin. over the biological ranges of Table 1, alongside
numerical simulations (see Methods). Numerical results were
similar regardless of whether the OR, AND, or MAJORITY rules
were used, and analytical derivations for the AND and OR rule
were equivalent by symmetry. The MAJORITY rule may be
biologically relevant in some cases, but this rule is mathematically
more complex. Therefore, the MAJORITY rule was simulated
numerically but not derived analytically. Numerical simulations
were intractable for large N, preventing us from simulating
biological values of N or cases where M,,N. Numerical results
are expected to approach the analytical curves at large N,
however. Additionally, these equations are not dependent on N,
and therefore incorporate the case M,,N as well.
The number of unique output states V is a decreasing function
of ,kin., and robustness R is an increasing function of ,kin.
dependent on the mutation rate. Furthermore, R increases rapidly
with ,kin. above 1, but saturates quickly for values above 5.
Therefore, adding redundancy via ,kin. has a high marginal
benefit to robustness for low ,kin., but as ,kin. increases, the
incremental benefit to R may be outweighed by the cost to the
unique outputs achievable by the network. Marginal utility to
robustness of increasing ,kin. shrinks rapidly above ,5, while at
the same time incurring a cost on the number of feasible unique
output states. This ,kin. value is close to the naturally occurring
values shown in Table 1.
Discussion
Trade-offs between robustness and efficiency
In addition to the quantitative conclusions of the Boolean
model, other trade-offs might also be involved in determining the
values of the observed parameters. There may be an additional
evolutionary cost for attaining and storing the genetic information
required for each link, and increasing the numbers of controllers
and links may also incur a cellular cost for resources dedicated to
protein synthesis. Many-to-many configurations would therefore
be expected to emerge as a strategy for maximizing both
robustness and the efficient use of resources, and observed
network parameters reflect a balance between these opposing
influences. These considerations are consistent with the differences
in values of ,kin. among human and bacterial transcription
factor networks (Table 1). As pointed out by r/K selection theory
[21], these two organisms use very different life history strategies,
with bacteria favoring more rapid reproduction (facilitated by a
smaller genome size) and lower offspring robustness.
Biological networks and mathematical models of
robustness
Robustness is a key feature of biological systems [22] and has
been shown in different types of mathematical models of biological
networks. Among these are Boolean network models, first
pioneered by Kaufmann [3] [4]. Boolean rules have been used
to model specific interactions in small, well-characterized biolog-
ical pathways [5,6,7], and entropy-based methods have been used
to examine the robustness and flexibility of a small pathway to
achieve functional outputs [23].
Buldyrev et al [24] have presented a model of the vulnerability
of interdependent networks. Interestingly, nodes from the two
interdependent networks were connected among each other only
by one-to-one links, providing additional evidence for the lack of
robustness of this type of structure.
Besides structural robustness to the removal of nodes or links,
several authors have also investigated dynamical robustness. For
example, within a framework of dynamical modeling based on
attractors, Li et al [6] have shown that the cell-cycle network is
extremely stable and robust for its function. The robustness of
dynamical networks with different degree distributions has been
analyzed in terms of the presence or absence of attractor states also
by other authors [25]. The robustness is given by the tendency of
the system to return to the attractor states after perturbation.
Klemm and Bornholdt [26] have investigated the reliability of
information processing in networks of noisy switches with
Controller-Target Biological Networks
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in future work the behavior of the control structures and
parameters we have described in this paper within these different
dynamical models.
In contrast to previous studies, in this paper we analyze the
properties of bipartite networks in terms of the allowed
configurations that can be realized in the target nodes for all
input states. The dynamics are therefore limited to a single step.
Also in contrast to other studies, here we consider robustness in
terms of how the number of accessible states is reduced by deleting
links. We use this entropy of target states as a tool to examine the
general parameter dependence of robustness and flexibility of
Boolean control in bipartite networks of arbitrary size. Specifically
we examine the dependence of robustness and flexibility on kin,
one of the parameters shown to be conserved in our statistical
analysis of biological networks.
Enrichment of gene categories in network targets
As shown in more detail in Text S1.2, we used the three human
networks to explore whether certain categories of nodes may be
more highly targeted than others. Controller nodes appeared in
the target sets more than expected (Table S1). Highly targeted
genes in all networks shared many significantly enriched Gene
Ontology (GO) terms [27] involved in transcription, regulation,
and development (Table S2). Conversely, sparsely targeted genes
tended to be enriched in GO terms involving biological ‘‘effector’’
processes, such as metabolism, transport, and the response to
stimulus (Table S3). Additionally, human genes regulated by all
three types of controller molecule were almost always themselves
involved in regulation (Figure S1). Together these data suggest that
cells use different control network topologies depending on the
type of target genes. Control nodes themselves are under the
heaviest combinatorial control, and by more different types of
controller, while downstream effector genes are regulated by fewer
controllers. These observations might be relevant to the design of
strategies for pharmacological combinatorial control.
Implications of the existence of biomimetic drug-target
bipartite networks
Our results show that pharmacological sets with biomimetic
statistical properties can be built from kinase inhibitor libraries
available now in companies and this paper intends to provide a
Figure 3. Mathematical model of the number and robustness of output states in a bipartite control network. We explored the
dependence of these quantities on the average incoming links per target ,kin., number of controllers M, number of targets N, and mutation rate
c=N (or links deleted as a fraction of N, robustness equation only). Shown are averages of 1000 numerical simulations with M=N=10, and c=N =0.1.
Analytical solutions for robustness and unique output states using the OR rule were also derived and plotted (lower right), and found to be identical
or a close approximation to simulations, respectively (see Methods). Both quantities were independent of N in numerical and analytical solutions.
These results suggest that marginal utility to robustness of increasing ,kin. shrinks rapidly above ,5, while at the same time incurring a cost on the
degree of freedom of output states.
doi:10.1371/journal.pone.0029374.g003
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this biomimetic approach to pharmacology.
The evolutionarily conservation of the many-to-many structure
and of the statistical parameters and the results of our
mathematical model suggests that pharmacological control
strategies should be designed similarly. Current efforts to develop
specific, targeted therapies follow the one-to-one approach to drug
therapy [28,29]; in other words, the ideal aim of drug discovery is
seen as having one drug for each molecular target, with no target
overlap. More traditional therapies are often less specific (one-to-
many in Figure 1) and some effective targeted therapies have also
been found to be non-specific and might fit this category [30,31].
An alternative approach would seek combinations of drugs that
control the activation state of a large proportion of a set of targets
in a many-to-many fashion, similar to combinatorial regulation of
cellular networks, rather than intervening at a single or small
number of targets. Combinatorial therapies could be found by
searching within biomimetic pharmacological sets having the same
network structure as naturally occurring biological systems.
Evolution conducts a similar search using all controller molecules
encoded in the genome, in order to find the optimal subsets to be
expressed in a particular cell type. The many-to-many approach
may be more robust to drug resistance and to genetic and
environmental variation, as suggested by our mathematical model.
There are two recent developments that make testing this
approach a realistic possibility. The first is the emergence of high-
throughput in vitro or in vivo search algorithms for efficiently
optimizing large combinations of drugs from within candidate sets
[32,33,34,35]. These algorithms are essential to overcome the
exponentially growing possibilities of the combinatorial space. It is
clearly not sufficient for pharmacological sets to have an optimal
network control structure, and these methods permit an efficient
search for the appropriate component drugs. The second is the
availability of large libraries of suitable molecular tools, the most
promising being kinase inhibitors, as shown by our results. The
518 identified protein kinases in the human genome account for
20–30% of the drug discovery programs of many companies [36]
and it is possible to characterize the target specificity of the
inhibitors using panels of kinases [37].
Limitations
One limitation of this analysis is that the bipartite model is only
a first approximation of reality, since many nodes in the target
layer are controllers themselves, interactions downstream of the
targets can feed back to the control layer, and nodes often do
interact with other nodes of the same class. Additionally, links in
our model are unweighted, whereas biological interactions can be
inhibitory or excitatory, with varying strength of action. It is not
possible to determine theoretically which is the appropriate level of
simplification for this model, which we apply both to naturally
occurring biological control and to pharmacological control. Only
the efficacy of the experimental interventions mentioned above
will allow us to determine if any usefulness is retained. It should
also be noted that these interaction datasets are incomplete, have
varying levels of confidence, and are not fully validated. The
quantitative patterns we have described are, however, common to
datasets of very different origin and therefore cannot reasonably be
explained by experimental noise or bias present in each dataset.
Conclusion
We have shown the generality of several network metrics of
biological combinatorial control. This discovery, together with our
increasing understanding of the mathematical principles underly-
ing biological control structures and their property of efficient
robustness, serve as building blocks for a new approach to
pharmacological control of biological systems. This approach
utilizes naturally occurring drug promiscuity to build sets with
biomimetic properties, such as many-to-many targeting, very wide
coverage of the target set, and redundancy of incoming links per
target. Importantly, these are quantitative properties of the
network and cannot be described by listing features of individual
drugs, such as selectivity. We therefore do not simply suggest the
use of nonselective therapeutic agents but propose testing the use
of drugs to build layers of control similar to those present within
cells. This suggestion is also consistent with a recent paper from
the Barabasi group showing that biological networks can be fully
controlled only by acting on at least 80% of the nodes [38,39].
This systems-level approach to pharmacological intervention
would mimic combinatorial strategies that are ubiquitous in
Nature.
Materials and Methods
Data and software
Predicted human microRNA-mRNA binding sites were down-
loaded from the TargetScan database [40] release 5.1 (http://www.
targetscan.org). Only conserved targets of conserved miRNA
families were used (made available in the file ‘‘Predicted_Targets_
Info.txt’’). Human transcription factor binding sites were gathered
from the TRANSFAC database [41]. The network was trimmed for
binding sites that could be mapped directly to a transcription factor
withanEntrezGeneidentifier(reducing615DNAbindingdomains
to 389 known transcription factors and 13362 DNA binding sites to
9284 binding sites). Yeast transcription factor to gene regulations
were downloaded from the YeasTRACT database [42] (http://
www.yeastract.com). Human phosphorylation binding sites were
downloaded from the PhosphoPOINT database [43] (http://
kinase.bioinformatics.tw), using only sites in Category 3 (Known
Substrate) and Category 4 (Interacting Phospho-protein with
Known Substrate) [43]. Yeast phosphorylation binding sites were
extracted from the Phosphorylome database [44] website (http://
networks.gersteinlab.org/phosphorylome/). E. coli transcription
factor binding sites were downloaded from the RegulonDB
database [45] release 6.4 (http://regulondb.ccg.unam.mx). Parsing
and formatting of the data was performed in Python, when
necessary. All data analysis was performed in R. The Bioconductor
suite in R was used to perform all gene annotations (‘‘org.Hs.eg.db’’
package), and Gene Ontology enrichment analysis (‘‘GOstats
package’’).
Numerical simulations of the mathematical model were
performed in Matlab. All R and Matlab code is made available
at http://paternostrolab.org/.
Degree distribution analysis
The discrete analog to the continuous exponential distribution is
the geometric distribution
P(X~k)~p(1{p)
k{1,k[ 1,2,::: fg
which has expected value
E(X)~SkT~
1
p
:
Therefore, for a distribution with known expected value SkT~m,
p~
1
m
.
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function (cdf) avoids binning effects and displays every data point.
In Figure 2A, empirical cumulative distribution functions for each
network had their x-axis normalized by SkT and were plotted next
to the cdf of the geometric distribution
P(X§k)~(1{
1
m
)
k{1,
with the x range normalized by m. Similar curves were produced
by different m.1, converging to the curve in Figure 2A for m..1.
Bipartite random graph model
Figures 2B and 2C show binned histograms of the degree
distribution data, compared with histograms of the null distribu-
tion expected from a bipartite modification of the Erdo ¨s-Re ´nyi
random graph model [18]. In graph theory [46], this model links
any two nodes according to a probability p. Similarly, we can
consider bipartite random networks of controllers and targets with
the same number of control nodes M and target nodes N as each
biological network, and with the probability p of a link between
any control and any target node equal to the measured link density
D. Random bipartite graphs have incoming and outgoing links
according to the binomial distribution, using D as the probability
parameter. Since the networks are large, the Poisson distribution
P(X~k)~
l
ke{l
k!
was used as an approximation to the binomial, with l=,k., with
,k.=MD for targets and ,k.=ND for controllers. The dashed
curves in Figure 2B and 2C are histograms of the expected Poisson
distribution of links for the M, N, and D of each network, using the
same binning as the biological data.
Sampling algorithms
In addition to the approach described in the results section, we
also developed an alternative algorithm for sampling biomimetic
controller sets from a large bipartite network (e.g., selecting a
subset of kinase inhibitors from a pharmaceutical compound
library). The algorithm selects an arbitrarily sized subset of
controllers, given the desired monotonically decreasing distribu-
tion of incoming links for the target nodes and an ordered list of
target nodes.
First, the target list can optionally be ordered by one or many
biological criteria. In the case of the kinase inhibitor network,
kinase targets can be ranked using information such as disease
relevance, mutation status, protein expression, or phosphorylation
state.
Next, the desired continuous link distribution p(k) is discretized
to P[k] for k=[1,2,…,N], which assigns a desired integer number
of incoming links for each target node. In the case of the kinase
inhibitor network, this step assigns the highest incoming links
P[k=1] to the top-ranked kinase target, the second highest
incoming links P[k=2] to the second kinase in the list, and so on.
In this way, the algorithm generates an incoming link profile that
ensures that more important targets receive more incoming links
and therefore are more likely to be inhibited or regulated.
Finally, a linear programming algorithm selects the minimal set
of controllers (inhibitors) that satisfies or exceeds the incoming link
profile for the set of targets (kinase). The linear programming
problem is to minimize a binary vector x so that Ax$b, where x is
of the same length as the controller library and denotes whether a
node is selected as part of the subset, A is the adjacency matrix
describing the controller-target network links and b is the
incoming link profile for each target. Since each row of A
represents the connectivity of a single target node, the column
vector b=Ax is the sum of incoming links from the subset x for
every target in the network. Solutions to linear programming
problems may be degenerate, so multiple subset solutions may be
possible.
Mathematical model of a bipartite information
processing network
We neglect the feedback from targets to controllers. At the
molecular level, the details of biological interactions and signal
propagation are complex and idiosyncratic; therefore we used an
abstract model of signaling similar to Boolean networks. In this
model, control signals are represented by control node values of
either 1 or 0. Links are not weighted, passing input values to the
output node unaltered. Control signals reaching a target are then
computed by one of three rules, and the target’s output is a binary
value indicating its active/inactive state. The ‘‘OR’’ rule
designates that an output node is active if any of its connected
input nodes is active. The ‘‘AND’’ rule requires all inputs to be
active in order to activate the output node. The ‘‘MAJORITY’’
rule counts the number of incoming links, and activates the output
node if more than half of the inputs are active, otherwise the
output remains inactive. Bipartite networks using one of the three
rules are studied separately. Examples can be found in the
biological literature supporting the applicability of all three rules.
Standard descriptions of gene control by transcription factors state
that ‘‘each eukaryotic gene is therefore regulated by a committee
of proteins, all of which must be present to express the gene at its
proper level’’ [1]. In the same standard reference the analogy with
a microprocessor AND gate is explicitly made [1] for intracellular
signal transduction. Recent studies on multisite phosphorylation
by protein kinases describe cases where a proportion of sites above
a threshold number needs to be phosphorylated to switch on
degradation of a protein [47,48], a clear example of the
MAJORITY rule. In the cases of miRNAs many studies have
been reported describing clear effects of adding or silencing one
miRNA [49,50], which would be consistent with the OR rule. It s
clear, however, that these rules are only a very simplified
representation of actual biological control effects.
For a given number of controllers M and targets N, MƒN,
links are randomly added between controllers and targets with a
probability D, defined as the network density, or the total links
divided by the number of possible links M*N. Density can also be
calculated from the relationshipD~
SkinT
M
~
SkoutT
N
, where ,kin.
and ,kout. are the average incoming links kin to the N targets and
average outgoing links kout from the M controllers, respectively.
Robustness
The robustness to link deletion is defined as follows: given a
random bipartite network defined above, and a random binary
input sequence to the controller nodes, what is the fraction of
output nodes that change in response to the deletion of c links?
This is equivalent to asking, what is the probability that a single
output node changes in response to the deleted link?
Consider a single node having a fixed number of incoming links
kin and an output according to the OR rule. Define PF(kin) as the
probability that a target node is in a ‘‘fragile’’ condition, meaning
that deletion of one specific incoming link for that node will
change the output. Deleting a link to an inactive control node will
not change the output, so the only fragile state in the OR case is to
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input, out of all 2kin possible binary sequences of inputs. Therefore,
PF(kin)~
kin
1
  
1
2kin
~
kin
2kin
:
Then, the probability Fc that an output node with kin incoming
links changes in response to c randomly deleted links in a network
containing L links is
Fc(kin)~
c
L
PF(kin):
This expression takes into account that c/L is the probability of
hitting the ‘‘fragile’’ link. The robustness of a target with kin
incoming links can then be defined as
R(kin)~1{Fc(kin):
This quantity can be averaged over the target nodes by taking
an expectation value over the degree distribution according to
SRT~
X M
k~1
Rk in ðÞ Pk in ðÞ ,
where P(kin) is the degree distribution of incoming links. This is
the quantity plotted in Fig. 3.
Number of output states
We define output states V as the total number of unique binary
output sequences that our bipartite network can achieve. This
quantity has a maximum of 2
M for a one-to-one network (see
Figure 1). We can estimate V for large networks by considering
first the output entropy for a single output node with kin incoming
links. The single node entropy is
S(kin)~{qkin(0)log2qkin(0){qkin(1)log2qkin(1),
where qk is the probability of occurrence of each output state. For
the ‘‘OR’’ rule, only when all inputs are zero is the output also
inactive, therefore
qkin(0)~
1
2kin
, qkin(1)~1{
1
2kin
:
Inserting values for qk,
S(kin)~
kin
2kin
{(1{
1
2kin
)log2(1{
1
2kin
):
Using
ln(1{x)~{
X ?
g~1
xg
g
,
We obtain
S(kin)~
kin
2kin
z
1
ln2
1{
1
2kin
   X ?
g~1
1
g2gkin
:
As for the robustness, we can take an expectation value of the
entropy over the degree probability distribution
SST~
X M
k~1
Sk in ðÞ Pk in ðÞ :
The total number of states can then be estimated using V&2MSST.
In Figure 3 we use a truncation of the series for S(kin)t og=3.
Expected values
We provide here some expressions that are useful to calculate
the expectation values of the entropy and robustness over the kin
degree distributions. These expectation values are calculated
according to the general expression
SfT~
X M
k~1
fk in ðÞ Pk in ðÞ ,
where P(kin) is the degree distribution of incoming links and f is a
function of kin.
Note that both robustness and entropy can be expressed in
terms of the quantities S
kin
2kinT and S
1
2gkinT, with g integer. These
expected values can be explicitly calculated for an exponential
(geometric) distribution P(kin)~
1
SkinT
1{
1
SkinT
   kin{1
, which
gives
S
k
2kin
T~
2SkinT
1zSkinT ðÞ
2 , and
S
1
2gkin
T~
1
1z 2g{1 ðÞ SkinT
:
If the links are randomly distributed with kin[ 1,2,:::M fg ,a si n
the bipartite random network model described above, then P(kin)i s
the binomial distribution. Assuming a large network, however,
P(kin) is approximated by the Poisson distribution
P(kin)~
SkinT{1 ðÞ
kin{1e{(SkinT{1)
kin{1 ðÞ !
:
Note that we are not including kin~0 in our analysis. Using this
distribution we obtain
S
kin
2kin
T~
1
4
e
1{SkinT
2 1zSkinT ðÞ ,
and
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1
2gkin
T~2{ge
2{g SkinT{1 ðÞ {SkinTz1:
The resulting curves are similar for Poisson and exponential link
distributions (see Figure S7, leading to similar optimal values SkinT
that maximize both robustness and entropy.
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